Nurix Therapeutics (NRIX) EBITDA Margin (2019 - 2026)
Nurix Therapeutics (NRIX) reported EBITDA Margin of 1479.45% for Q1 2026, down 113878.0% year-over-year from N/an in Q1 2025, and down 141.73% quarter-over-quarter from 612.03% in Q4 2025.
Nurix Therapeutics (NRIX) EBITDA Margin (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 8 years of EBITDA Margin data on file, last reported at 1479.45% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 1479.45%, down 113878.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 738.0% (down 32913.0% YoY), and the FY2025 annual result was 340.16%, up 5036.0% from the prior year.
- EBITDA Margin retreated to 1479.45% in Q1 2026 per NRIX's latest filing, from 612.03% in the prior quarter.
- Over five years, EBITDA Margin peaked at 87.25% in Q2 2023 and troughed at 1479.45% in Q1 2026.
- A 5-year average of 496.65% and a median of 401.42% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2026: EBITDA Margin jumped 41877 bps in 2023, then plunged 113878 bps in 2026.
- A 5-year view of EBITDA Margin shows it stood at 717.82% in 2022, then jumped by 58 bps to 299.06% in 2023, then tumbled by 63 bps to 486.73% in 2024, then dropped by 26 bps to 612.03% in 2025, then plunged by 142 bps to 1479.45% in 2026.
- Business Quant data shows NRIX's EBITDA Margin at 1479.45% in Q1 2026, 612.03% in Q4 2025, and 1157.65% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Nurix Therapeutics | 1.93 Bn | 1.39 Bn | - | -1,479.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -1,479.45% |
| Nov 30, 2025 | -612.03% |
| Aug 31, 2025 | -1,157.65% |
| May 31, 2025 | -322.15% |
| Feb 28, 2025 | -340.67% |
| Nov 30, 2024 | -486.73% |
| Aug 31, 2024 | -433.83% |
| May 31, 2024 | -401.42% |
| Feb 29, 2024 | -272.65% |
| Nov 30, 2023 | -299.06% |
| Aug 31, 2023 | -216.67% |
| May 31, 2023 | -87.25% |
| Feb 28, 2023 | -338.60% |
| Nov 30, 2022 | -717.82% |
| Aug 31, 2022 | -432.93% |
| May 31, 2022 | -399.89% |
| Feb 28, 2022 | -444.28% |
| Nov 30, 2021 | -513.16% |
| Aug 31, 2021 | -282.84% |
| May 31, 2021 | -372.50% |